Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP.

EMBO J. 2019 Jun 26:e95874. doi: 10.15252/embj.201695874. [Epub ahead of print]

PMID:
31267558
2.

Melanoma patients with additional primary cancers: a single-center retrospective analysis.

Dimitriou F, Mangana J, Curioni-Fontecedro A, Rechsteiner M, Turko P, Braun RP, Dummer R, Cheng PF.

Oncotarget. 2019 May 21;10(36):3373-3384. doi: 10.18632/oncotarget.26931. eCollection 2019 May 21.

3.

Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis.

Rodewald AK, Rushing EJ, Kirschenbaum D, Mangana J, Mittmann C, Moch H, Lugassy C, Barnhill RL, Mihic-Probst D.

J Cutan Pathol. 2019 Mar 30. doi: 10.1111/cup.13465. [Epub ahead of print]

PMID:
30927294
4.

Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.

Mangana J, Dimitriou F, Braun R, Ludwig S, Dummer R, Barysch MJ.

Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000593. [Epub ahead of print]

PMID:
30870270
5.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJ.

J Natl Cancer Inst. 2019 Mar 13. pii: djz034. doi: 10.1093/jnci/djz034. [Epub ahead of print]

PMID:
30863861
6.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
7.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.

Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L.

J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2.

8.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.

Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L.

J Immunother. 2019 Apr;42(3):89-93. doi: 10.1097/CJI.0000000000000255.

PMID:
30768543
9.

Serum S100B Levels in Melanoma.

Frauchiger AL, Dummer R, Mangana J.

Methods Mol Biol. 2019;1929:691-700. doi: 10.1007/978-1-4939-9030-6_43.

PMID:
30710305
10.

Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.

Mangana J, Buset CS, Dummer R.

JAMA Oncol. 2019 Jan 24. doi: 10.1001/jamaoncol.2018.6431. [Epub ahead of print] No abstract available.

PMID:
30676614
11.

Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.

Dimitriou F, Mangana J, Micaletto S, Braun RP, Dummer R.

Melanoma Res. 2019 Feb;29(1):107-108. doi: 10.1097/CMR.0000000000000544. No abstract available.

PMID:
30557221
12.

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):686-692. doi: 10.1111/jdv.15363. Epub 2018 Dec 13.

PMID:
30468696
13.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
14.

A new B-Raf inhibitor combo for advanced melanoma.

Barysch MJ, Mangana J, Dummer R.

Oncotarget. 2018 Oct 2;9(77):34457-34458. doi: 10.18632/oncotarget.26171. eCollection 2018 Oct 2. No abstract available.

15.

Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.

Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, Mangana J, Müllhaupt B, Jenni F, Misselwitz B.

Transplant Direct. 2018 Jul 20;4(8):e376. doi: 10.1097/TXD.0000000000000814. eCollection 2018 Aug.

16.

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread.

Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, Amann VC, Levesque MP, Dummer R, Baluk P, McDonald DM, Detmar M.

Sci Adv. 2018 Aug 8;4(8):eaat4758. doi: 10.1126/sciadv.aat4758. eCollection 2018 Aug.

17.

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R.

J Immunother. 2019 Jan;42(1):29-32. doi: 10.1097/CJI.0000000000000236.

PMID:
29939877
18.

Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.

Häfliger EM, Ramelyte E, Mangana J, Kunz M, Kazakov DV, Dummer R, Cheng PF.

Melanoma Res. 2018 Oct;28(5):442-450. doi: 10.1097/CMR.0000000000000465.

PMID:
29847461
19.

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.

Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.

PMID:
29843107
20.

Methadone-Not a magic bullet in melanoma therapy.

Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R.

Exp Dermatol. 2018 Jun;27(6):694-696. doi: 10.1111/exd.13543.

PMID:
29577418
21.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
22.

Sarcoid-like reactions in patients receiving modern melanoma treatment.

Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, Franzen D, Kamarachev J, Braun R, Dummer R, Mangana J.

Melanoma Res. 2018 Jun;28(3):230-236. doi: 10.1097/CMR.0000000000000437.

23.

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Tétu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Michielin O, Lebbe C.

Eur J Cancer. 2018 Apr;93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12. No abstract available.

PMID:
29449059
24.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

25.

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.

Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, Horak C, Levesque M, Dummer R, Cheng PF.

Neoplasia. 2018 Feb;20(2):218-225. doi: 10.1016/j.neo.2017.12.002. Epub 2018 Jan 12.

26.

Update on adjuvant melanoma therapy.

Dimitriou F, Braun RP, Mangana J.

Curr Opin Oncol. 2018 Mar;30(2):118-124. doi: 10.1097/CCO.0000000000000432. Review.

27.

Electrical Impedance Spectroscopy in Skin Cancer Diagnosis.

Braun RP, Mangana J, Goldinger S, French L, Dummer R, Marghoob AA.

Dermatol Clin. 2017 Oct;35(4):489-493. doi: 10.1016/j.det.2017.06.009. Epub 2017 Aug 7. Review.

PMID:
28886804
28.

Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome).

Mangana J, Guenova E, Kerl K, Urosevic-Maiwald M, Amann VC, Bayard C, Dummer R, French LE.

Case Rep Dermatol. 2017 Mar 21;9(1):74-79. doi: 10.1159/000458752. eCollection 2017 Jan-Apr.

29.

Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.

Bossart S, Thurneysen S, Rushing E, Frontzek K, Leske H, Mihic-Probst D, Nagel HW, Mangana J, Goldinger SM, Dummer R.

Oncologist. 2017 Jun;22(6):749-753. doi: 10.1634/theoncologist.2016-0366. Epub 2017 May 30.

30.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

31.

Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.

Urosevic-Maiwald M, Mangana J, Dummer R.

Ann Oncol. 2017 Jul 1;28(7):1673-1675. doi: 10.1093/annonc/mdx187. No abstract available.

PMID:
28459947
32.

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.

Amann VC, Hoffmann D, Mangana J, Dummer R, Goldinger SM.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1638-1640. doi: 10.1111/jdv.14268. Epub 2017 May 8.

PMID:
28401596
33.

A Report of Two Cases of Solid Facial Edema in Acne.

Kuhn-Régnier S, Mangana J, Kerl K, Kamarachev J, French LE, Cozzio A, Navarini AA.

Dermatol Ther (Heidelb). 2017 Mar;7(1):167-174. doi: 10.1007/s13555-017-0173-6. Epub 2017 Feb 6.

34.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM.

Melanoma Res. 2017 Jun;27(3):231-237. doi: 10.1097/CMR.0000000000000338.

35.

Developments in targeted therapy in melanoma.

Amann VC, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, Dummer R, Mangana J.

Eur J Surg Oncol. 2017 Mar;43(3):581-593. doi: 10.1016/j.ejso.2016.10.014. Epub 2016 Nov 5. Review.

36.

A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis.

Jenni D, Karpova MB, Mühleisen B, Mangana J, Dreier J, Hafner J, Dummer R.

ESMO Open. 2016 Jan 18;1(1):e000003. eCollection 2016.

37.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD.

Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16.

38.

An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.

Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R.

Br J Dermatol. 2016 Nov;175(5):966-978. doi: 10.1111/bjd.14727. Epub 2016 Sep 19.

39.

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages.

Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, Dummer R, Contassot E, French LE.

Sci Rep. 2016 Jul 18;6:29914. doi: 10.1038/srep29914.

40.

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

Sönnichsen A, Saulite I, Mangana J, Kerl K, Mehra T, Desislava I, Chang YT, Petrausch U, Schmid-Grendelmeier P, Hoetzenecker W, Cozzio A, Guenova E.

J Dermatolog Treat. 2016 Oct;27(5):436-8. doi: 10.3109/09546634.2015.1136048. Epub 2016 Feb 10.

PMID:
26864191
41.

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma.

Mangana J, Felderer L, Cheng P, French LE, Dummer R, Schad K.

Ann Dermatol. 2015 Dec;27(6):780-1. doi: 10.5021/ad.2015.27.6.780. Epub 2015 Dec 7. No abstract available.

42.

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.

Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, Dummer R, Goldinger SM.

Br J Dermatol. 2016 Apr;174(4):823-30. doi: 10.1111/bjd.14347. Epub 2016 Mar 2.

PMID:
26659191
43.

Efficacy and safety of oral alitretinoin in severe oral lichen planus--results of a prospective pilot study.

Kunz M, Urosevic-Maiwald M, Goldinger SM, Frauchiger AL, Dreier J, Belloni B, Mangana J, Jenni D, Dippel M, Cozzio A, Guenova E, Kamarachev J, French LE, Dummer R.

J Eur Acad Dermatol Venereol. 2016 Feb;30(2):293-8. doi: 10.1111/jdv.13444. Epub 2015 Oct 27.

PMID:
26507685
44.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

45.

Sorafenib in melanoma.

Mangana J, Levesque MP, Karpova MB, Dummer R.

Expert Opin Investig Drugs. 2012 Apr;21(4):557-68. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. Review.

PMID:
22394203
46.

Prevalence of Merkel cell polyomavirus among Swiss Merkel cell carcinoma patients.

Mangana J, Dziunycz P, Kerl K, Dummer R, Cozzio A.

Dermatology. 2010;221(2):184-8. doi: 10.1159/000315067. Epub 2010 Jul 30.

47.

Melanoma after laser therapy of pigmented lesions--circumstances and outcome.

Zipser MC, Mangana J, Oberholzer PA, French LE, Dummer R.

Eur J Dermatol. 2010 May-Jun;20(3):334-8. doi: 10.1684/ejd.2010.0933. Epub 2010 Apr 27.

48.

Possible interaction between topical terbinafine and acenocoumarol.

Morales-Molina JA, Arrebola MA, Robles PA, Mangana JC.

Ann Pharmacother. 2009 Nov;43(11):1911-2. doi: 10.1345/aph.1M299. Epub 2009 Oct 20. No abstract available.

PMID:
19843835
49.

Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Dummer R, Mangana J.

Biologics. 2009;3:169-82. Epub 2009 Jul 13.

50.

Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.

Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, French LE, Dummer R.

Eur J Dermatol. 2008 Sep-Oct;18(5):566-70. doi: 10.1684/ejd.2008.0490. Epub 2008 Aug 8.

Supplemental Content

Loading ...
Support Center